Form 4: Ligand Pharmaceuticals CLO Andrew Reardon Sells 500 Shares Under Pre-Arranged Plan
Insider Transaction Report
Ligand Pharmaceuticals' Chief Legal Officer and Secretary, Andrew Reardon, reported the sale of 500 shares of common stock for approximately $114.54 per share, reducing his direct beneficial ownership to 32,403 shares.
Summary
- Andrew Reardon, the Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc. (LGND), reported the sale of 500 shares of the company's common stock.
- The transaction took place on June 10, 2025.
- The shares were sold at a price of $114.5414 per share.
- Following this sale, Mr. Reardon directly beneficially owns 32,403 shares of Ligand Pharmaceuticals common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
Sentiment
Score: 5
Explanation: Neutral. The document is a standard insider transaction disclosure. While an insider sale can be viewed with caution, the presence of a 10b5-1 plan mitigates some concerns, suggesting a routine liquidity event rather than a signal of negative company prospects.
Positives
- The sale was conducted under a Rule 10b5-1 plan, indicating a pre-arranged transaction designed to comply with insider trading regulations and provide transparency.
Negatives
- An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.
- The sale of 500 shares by a key officer reduces their direct beneficial ownership in the company.
Future Outlook
The document, an SEC Form 4, is a disclosure of an insider stock transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This SEC Form 4 filing details an individual insider transaction and does not provide broader insights into industry trends or competitive landscape. It is specific to the reporting person and Ligand Pharmaceuticals.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was executed under a Rule 10b5-1 plan, which is a pre-arranged trading plan designed to allow insiders to sell shares at a predetermined time or price, thereby avoiding accusations of trading on material non-public information. | 06/10/2025 | Enhances transparency and compliance regarding insider stock transactions, reducing potential legal and reputational risks associated with non-compliant trading practices. |
Related Party Transactions
- Sale of 500 shares of common stock by Andrew Reardon, an officer (CLO & Secretary) of Ligand Pharmaceuticals, to the open market.
Stakeholder Impact
- Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan suggests it's a routine liquidity event rather than a reflection of management's view on future prospects. The reduction in direct ownership by a key officer could be viewed with slight caution.
Key Dates
| Date | Description |
|---|---|
| 06/10/2025 | Date of transaction (sale of common stock). |
| 06/12/2025 | Date the Form 4 was signed and filed with the SEC. |
Keywords
Ligand Pharmaceuticals, LGND, SEC Form 4, Insider Trading, Stock Sale, Andrew Reardon, Officer Transaction, Common Stock, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.